What is it about?
This study highlights the real-world success of Lenire by Neuromod, a bimodal neuromodulation tinnitus treatment device. Researchers conducted a retrospective chart review of tinnitus patients treated with Lenire at New York Hearing Doctors (NYHD). Lenire’s treatment method combines audio played through headphones and mild pulses to the tongue to retrain how the brain perceives tinnitus signals. The analysis focused on 104 patients with bothersome tinnitus (moderate or worse) and showed Lenire’s clinical trial success was replicable in an everyday clinical practice.
Featured Image
Photo by Milad Fakurian on Unsplash
Why is it important?
Tinnitus impacts 15% of the global adult population. For the millions living with constant ringing, hissing, buzzing and other noise in their ears, this study offers compelling evidence that significant relief is possible in a standard clinical setting using Lenire: ● Exceptional Success: 81.8% of 104 patients with bothersome tinnitus reported clinically meaningful relief after 12-weeks of Lenire. ● Rapid Improvement: 72.6% of these patients reported clinically significant relief from tinnitus after just 6-weeks. ● Meaningful Change: Patients saw an average 23.8-point drop in their Tinnitus Handicap Inventory (THI) score. This is more than three times the accepted minimum point reduction of 7-points on the THI to meet the clinical significance threshold. ● Scalable Consistency: These results almost mirror earlier peer reviewed real-world findings from Alaska Hearing & Tinnitus, proving that Lenire is a scalable, consistently effective tinnitus treatment option across different clinical environments.
Perspectives
“New York Hearing Doctors stay on the cutting-edge of tinnitus care through the introduction of modern technologies like Lenire and leveraging research to consistently refine our treatment methodologies. The combination of our personalized approach to tinnitus care and the remarkable effectiveness of Lenire, we are seeing life-changing treatment outcomes for our patients.” Dr. Craig Kasper, Au.D., Founder of NYHD
Hubert H Lim
University of Minnesota Twin Cities
Read the Original
This page is a summary of: Bimodal Neuromodulation for Tinnitus in a Clinical Practice Setting: Clinically Significant Benefit for Patients With Moderate or Worse Symptoms, American Journal of Audiology, January 2026, American Speech-Language-Hearing Association (ASHA),
DOI: 10.1044/2025_aja-25-00090.
You can read the full text:
Resources
Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting
The first real-world study of patients treated with Lenire in the US was published in April 2025 and showed consistent results,
First Real-World Evidence Utilizing the Multidimensional Tinnitus Functional Index to Assess Treatment Impact with Bimodal Neuromodulation
This is the first real-world study to assess the therapeutic effects of Lenire on tinnitus using the Tinnitus Functional Index (TFI), a multidimensional instrument designed to capture tinnitus severity and treatment responsiveness. The study correlates findings with the Tinnitus Handicap Inventory (THI), a well-established tool that assesses the perceived functional, emotional, and catastrophic impact of tinnitus that was used in previous clinical trials and real-world studies. The use of an alternative validated outcome measure in a real-world study may add more feasible, relevant and patient-centered research findings to the body of evidence for Lenire, while maintaining scientific credibility.
Contributors
The following have contributed to this page
